MyFinsight
Home
About
Contact
amgn: the income statement
Download
Download image
Non Us
$445M
(9.88%↑ Y/Y)
US
$1,408M
(46.97%↑ Y/Y)
Non Us
$122M
(-18.67%↓ Y/Y)
US
$162M
(22.73%↑ Y/Y)
Revenue From Contract
With Customer...
$320M
(3.23%↑ Y/Y)
Revenue From Contract
With Customer...
$377M
(40.15%↑ Y/Y)
Non Us
$254M
(9.48%↑ Y/Y)
US
$103M
(-1.90%↓ Y/Y)
Non Us
$134M
(-4.29%↓ Y/Y)
US
$225M
(-5.46%↓ Y/Y)
Non Us
$124M
(11.71%↑ Y/Y)
US
$333M
(-3.48%↓ Y/Y)
Non Us
$156M
(73.33%↑ Y/Y)
US
$236M
(-0.42%↓ Y/Y)
Non Us
$42M
(600.00%↑ Y/Y)
US
$518M
(7.47%↑ Y/Y)
Non Us
$124M
(12.73%↑ Y/Y)
US
$417M
(44.29%↑ Y/Y)
Non Us
$182M
(8.33%↑ Y/Y)
US
$357M
(-4.29%↓ Y/Y)
Non Us
$112M
(7.69%↑ Y/Y)
US
$473M
(2.83%↑ Y/Y)
Non Us
$6M
(-25.00%↓ Y/Y)
US
$574M
(-29.74%↓ Y/Y)
Non Us
$352M
(23.08%↑ Y/Y)
US
$442M
(57.30%↑ Y/Y)
Non Us
$333M
(-8.01%↓ Y/Y)
US
$806M
(18.01%↑ Y/Y)
Other Products
$1,853M
(35.95%↑ Y/Y)
Vectibix
$284M
(0.71%↑ Y/Y)
KRYSTEXXA
$320M
(3.23%↑ Y/Y)
TEZSPIRE
$377M
(40.15%↑ Y/Y)
Aranesp
$357M
(5.93%↑ Y/Y)
Kyprolis
$359M
(-5.03%↓ Y/Y)
Nplate
$457M
(0.22%↑ Y/Y)
BLINCYTO
$392M
(19.88%↑ Y/Y)
TEPEZZA
$560M
(14.75%↑ Y/Y)
EVENITY
$541M
(35.59%↑ Y/Y)
Xgeva
$539M
(-0.37%↓ Y/Y)
Otezla
$585M
(3.72%↑ Y/Y)
Enbrel
$580M
(-29.70%↓ Y/Y)
Repathaevolocumab
$794M
(40.04%↑ Y/Y)
Prolia
$1,139M
(9.00%↑ Y/Y)
Product And Service
Other
$420M
(19.32%↑ Y/Y)
Product
$9,137M
(12.10%↑ Y/Y)
Total revenues
$9,557M
(12.40%↑ Y/Y)
Other income, net
$2,080M
(13.66%↑ Y/Y)
Operating income
$2,526M
(23.40%↑ Y/Y)
Total operating
expenses
$7,031M
(8.91%↑ Y/Y)
Income before income
taxes
$3,921M
(26.44%↑ Y/Y)
Interest expense, net
$685M
(-11.73%↓ Y/Y)
Other
$329M
(363.38%↑ Y/Y)
Selling, general and
administrative
$1,720M
(5.85%↑ Y/Y)
Research and development
$1,900M
(31.03%↑ Y/Y)
Cost of sales
$3,082M
(-6.89%↓ Y/Y)
Net income
$3,216M
(13.64%↑ Y/Y)
Provision for income taxes
$705M
(160.15%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
amgen-blue-svg
AMGEN INC (AMGN)
amgen-blue-svg
AMGEN INC (AMGN)